recently, several bcl-2-related genes were cloned
(summarized in Ref. 20) . The bcl-x gene gives rise to short (bcl-X S ) and long (bcl-X L ) splice variants capable either of accelerating or inhibiting apoptosis, respectively. 21 The bax Introduction protein promotes apoptosis due to its ability to form heterodimers with bcl-2. 22 The ability of bcl-2 to suppress apoptosis Regulation of tissue development and cellular homeostasis is may also influence the treatment outcome of cancer patients. controlled by cell growth, differentiation and death. ProHigh-level expression of bcl-2 by leukemia cells is associated grammed cell death as the regulatory form of homeostasis with resistance to various apoptosis-inducing chemotherapy occurs mainly by apoptosis which is characterized by DNA regimens or radiotherapy.
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Most primary leukemia/ fragmentation between nucleosomes resulting in 200 bp DNA lymphoma tumor cells are resistant to anti-CD95-mediated ladder and specific morphological changes, including apoptosis and the resistance to apoptosis has been linked with chromatin condensation, membrane blebbing and appearthe expression of the bcl-2 protein. 25 Experimental overance of apoptotic bodies. [1] [2] [3] In contrast to apoptosis, necrosis expression of bcl-2 interferes with CD95-transduced apoptotic occurs during pathological cell death as a result of tissue signals. 26 Furthermore, in primary leukemia cells a correlation injury, complement attack, severe hypoxia, hyperthemia, lytic between bcl-2 expression and resistance to CD95-mediated viral infection and exposition to various toxins. 2, 4 apoptosis was observed. 15, 27 In other studies, however, no Apoptosis may develop following removal of growth factors correlation has been found for bcl-2 expression and resistance or by triggering of specific cell surface molecules, such as to CD95-mediated cytotoxicity. 28, 29 Resistance to apoptosis CD120a (TNFR p60) or CD95 (Fas/APO-1) (reviewed in Ref.
might be involved in the development of leukemias/ lymphomas by withstanding elimination of tumor cells through endogenous apoptosis pathways or chemotherapy.
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In our study, we analyzed a large series of newly diagnosed vitro crosslinking with anti-CD95 antibodies. In addition, the antagonistic anti-CD95 moAb, clone ZB4 (IgG 1 ; Immunotech), which has been shown to block CD95/CD95L-relevance of bcl-2 expression for the apoptosis behavior of ALL cells was investigated. mediated apoptosis, was used at concentrations of 0.1, 1.0 and 10 g/10 6 leukemic cells.
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Materials and methods
Assessment of CD95 and bcl-2 expression Cell samples CD95 antigen was detected by conventional immunofluoLeukemic blasts from 95 patients with newly diagnosed ALL of rescence staining of intact cells using phycoerythrine (PE)-coneither B lineage (n = 42) or T lineage (n = 53) affiliation were jugated anti-CD95 antibody (clone DX2; Pharmingen). 36 To included. The diagnosis was based on bone marrow (BM) evaluate the expression of the intracellular bcl-2 protein, leuaspirates, and the smears were classified as ALL according to kemic cells were fixed and permeabilized using the fixationthe FAB criteria using light microscopy and cytochemistry. 31 permeabilization kit (Fix & Perm; An-der Grub, Kaumberg, Immunophenotyping was carried out on leukemic blasts isoAustria) as recommended by the manufacturer. Bcl-2 antigen lated by standard Ficoll-Hypaque density gradient centrifugwas detected by the FITC-conjugated anti-bcl-2 antibody 124 ation, and cell-surface as well as cytoplasmic antigens were (Dako, Glostrup, Denmark). FITC-and PE-conjugated irreldetected using direct or indirect immunofluorescence (IF) evant mouse antibodies of the appropriate subclasses techniques as described elsewhere. 32, 33 The criteria for marker (Immunotech) were used as negative controls to determine positivity as well as the subclassification of B and T lineage background fluorescence. Immunofluorescence analysis was ALL followed the guidelines of the 'European Group for the performed on a FACScan flow cytometer (Becton Dickinson, Immunological Characterization of Leukemias' (EGIL) with B San Jose, CA, USA) using LYSYS II or CellQuest software lineage ALL being classified into pro-B, common, pre-B and (Becton Dickinson). Expression of antigens was quantified as mature B-ALL, and T lineage ALL into pro-T-, pre-T-, cortical relative fluorescence intensity (RFI), determined by the ratio and mature T-ALL. 34 of mean fluorescence intensity of cells stained for either CD95 Human leukemia cell lines of T (MOLT-3, RPMI-8402, or bcl-2 to mean fluorescence intensities of the corresponding P12/Ichikawa, PF-382) and B (207, 697, BV-173) lineage were negative controls. taken from the DSM Cell Culture Bank (Braunschweig, Germany). All cultures were free of mycoplasma contaminations.
Apoptosis assay
Apoptotic cells were detected by flow cytometric analysis of Cell purification and culture fixed, permeabilized and PI-stained samples as described elsewhere. 37 Briefly, a pellet of 0.5 × 10 6 leukemic cells was fixed Leukemic cells recovered from either fresh or cryopreserved by addition of 2 ml of ice-cold 70% ethanol for 1 h at 4°C. patient samples were purified by density gradient centrifugAfter washing the cells were resuspended in 0.5 ml PBS conation using Ficoll-Hypaque separation (Pharmacia, Uppsala, taining 1 mM EDTA, 0.05% Triton X-100 (Serva, Heidelberg, Sweden). Viability of cells was always more than 90% as Germany), and 50 g/ml PI, pH 7.5. Following the treatment determined by trypan blue or propidium iodide (PI) (Sigma, with 0.2 mg/ml RNase (type I-A; Boehringer Mannheim, Deisenhofen, Germany) exclusion. All samples contained Mannheim, Germany) for 30 min at room temperature in the more than 90% leukemic cells based on morphological cridark, the cells were stored at 4°C until analyzed. Cells terias. Functional assays with freshly isolated or thawed cells undergoing apoptosis were identified by flow cytometric of the same patient gave similar results. Leukemic cells were analysis of DNA histograms or dot plots of DNA content vs maintained in RPMI 1640 (Biochrom, Berlin, Germany) stanforward scatter using the LYSYS II or CellQuest software dard medium (SM) containing 2 mM L-glutamine, 100 U/ml (Becton Dickinson) and quantified as percentage of cells with penicillin and 100 g/ml streptomycin (Gibco BRL, Paisley, subdiploid DNA content. 37 UK). Cell lines were grown in SM, supplemented with 10-The extent of the specific CD95-mediated apoptosis (%) 20% heat-inactivated fetal calf serum (Gibco BRL) at 37°C in was assessed by a formula as described elsewhere:
28 an atmosphere of 7% CO 2 in air.
To assess spontaneous apoptosis, 0.5 × 10 6 cells/well were (CD95-mediated apoptosis − spontaneous apoptosis) × 100 cultured in 96-well microtiter plates (Nunc, Roskilde, (100 − spontaneous apoptosis) Denmark) using SM for 20 h at 37°C in a humidified atmosThe CD95-mediated apoptosis is the percentage of apoptotic phere of 7% CO 2 in air. To investigate the CD95-mediated cells in the presence of the anti-CD95 moAb, and the sponeffects, leukemic cells were preincubated with 1 g/10 6 cells taneous apoptosis is the percentage of apoptotic cells in the of anti-CD95 monoclonal antibody (moAb) DX2 (IgG 1 ; presence of the irrelevant control moAb or medium alone. Pharmingen, San Diego, CA, USA) for 30 min, washed twice with SM and cultured for an additional 20 h in the presence of sheep anti-mouse immunoglobulin (0.5 g/well) used to Morphology of apoptotic cells crosslink the DX2 antibody bound to CD95 protein on the surface of the cells. Alternatively, the cells were cultured for 20 h in the presence of the anti-CD95 moAb CH-11 (IgM;
For morphological analysis, apoptotic leukemia cells were first separated from viable cells by flow sorting using a FACS VanImmunotech, Marseille, France; 1 g/10 6 cells) which was shown to crosslink the CD95 protein on the cell surface tage cell sorter (Becton Dickinson). Morphology of the sorted cells was assessed by a MultiProbe 2010 confocal laser microdirectly. 35 As a negative control, cells were preincubated with irrelevant control antibodies. In selected experiments, the scope (Molecular Dynamics, Sunnyvale, CA, USA), equipped with a krypton-argon laser. Cell nuclei were stained with PI, excited at 568 nm wavelength and the emitted light was detected with a 590 nm long-pass filter. The size of the basic element of the fluorescence data collected (three-dimensional pixel or voxel) was 0.11 × 0.11 × 0.29 m 3 . The elaboration of the three-dimensional images and their reconstruction as surface-shaded projections was performed on a Silicon Graphics Indy workstation (Silicon Graphics, Mountain View, CA, USA) using the ImageSpace software (Molecular Dynamics).
Statistical analysis
Results are mean ± s.e.m. as indicated. Differences were evaluated using the two-tailed, non-parametric Mann-Whitney U-test for unpaired samples. P value of Ͻ0.05 was con-
Figure 2
Fluorescence histograms of two ALL samples which were sidered significant. To investigate the correlation between CD95 and bcl-2 that for the T lineage cases with 1.1 to 16 RFI was considerexpression, we stained the ALL samples for the intracellular ably broader. The surface expression of the CD95 antigen, bcl-2 ( Figure 2 ). All B-lineage cases were bcl-2 positive with analyzed in different subtypes of B lineage ALL (pro-B-ALL a mean RFI of 5.9 ± 0.7 (range: 1.38-18.72 RFI) ( Figure 3 ). n = 9, common-ALL n = 24, pre-B-ALL n = 9) did not show any Similarly, in all the T lineage cases bcl-2 protein could be significant differences in the CD95 surface expression detected with a mean RFI of 5.4 ± 0.5 (range: 1.1-11.33 RFI) (2.8 ± 0.5 vs 2.1 ± 0.3 vs 1.9 ± 0.5 RFI, respectively) ( Figure 1 ).
( Figure 3 ). There were no significant differences between the Similarly, the pro-T-/pre-T-ALL (n = 15), cortical T-ALL (n = 23) and mature T-ALL (n = 15) cases did not disclose different intensity of CD95 staining (4.4 ± 1.1 vs 5.4 ± 0.7 vs Figure 3 Intracellular expression of the bcl-2 protein in leukemia cells from patients with T and B lineage ALL. The leukemic cells were fixed, permeabilized and stained with the FITC-conjugated anti-bcl-2 moAb. Relative fluorescence intensities (RFI) of the samples were Figure 1 Surface expression of CD95 on leukemia cells from patients with T and B lineage ALL evaluated by flow cytometry. Avermeasured by flow cytometry and average values (mean ± s.e.m.) of RFI for the two different ALL groups and their immunophenotypic subage values (mean ± s.e.m.) of RFI estimated for the two different ALL groups and several immunophenotypic subgroups are presented. RFI groups were estimated. RFI is the ratio of mean fluorescence intensity of cells stained for bcl-2 to mean fluorescence intensity of the correis the ratio of mean fluorescence intensity of cells stained for CD95 to mean fluorescence intensity of the corresponding negative control.
sponding negative control. To assess the CD95-mediated specific apoptosis, the ALL cells were treated with anti-CD95 moAb (either DX2 or CH11), and the apoptosis was detected by flow cytometry. As shown in Table 1 , only in five cases did the extent of CD95-triggered B and T lineage ALL cells undergo spontaneous specific apoptosis exceed the value of 20%, and all of these apoptosis in culture cases were of T lineage (9%). However, we observed a substantial number of cases revealing a low but distinct susceptiIn the next set of experiments, we were interested in determinbility to crosslinking of CD95, especially in T lineage ALL ing the spontaneous apoptosis of ALL cells. The leukemia cells (28%) but also in B lineage ALL (10%). As summarized in were cultured for 20 h in SM after either thawing or fresh prep- Table 1 , the anti-CD95 moAb CH11 (IgM subclass) was more aration. Spontaneous apoptosis was determined using flow effective in induction of CD95-mediated apoptosis of leucytometric detection of cells with subdiploid DNA content in kemic cells than the DX2 anti-CD95 moAb (IgG 1 subclass) ethanol-fixed and PI-stained cell samples. The spontaneous crosslinked with a sheep-anti-mouse Ig. Subgrouping of the apoptosis lower than 10% was rated as negative. Spontaneous ALL cases according to their maturational stage did not reveal apoptosis was observed in 33 of the 42 B lineage (79%) and any significant differences in their susceptibility to CD95 trig-49 of 53 T lineage (92%) ALL cases (Figure 4 ). There was a gering. To analyze whether CD95-induced apoptosis depends significant difference (P Ͻ 0.05) between the mean values of on the intensity of CD95 cell surface expression by leukemic spontaneous apoptosis when comparing T and B lineage ALL cells, the specific CD95 RFI surface expression was correlated (mean: 31.8 ± 2.4% vs 26.4 ± 2.5, respectively). As shown in with the extent of CD95-mediated apoptosis. We were unable Figure 4 , most of the T lineage and B lineage cases showed to find a correlation between the level of CD95 surface either a low (10-30%) or moderate (30-50%) degree of sponexpression and the CD95-mediated effects (data not shown). taneous apoptosis. Some cases failed to demonstrate spon-A representative example of the spontaneous and CD95-taneous apoptosis (Figure 4 ). Subgrouping the T and B lineage mediated apoptosis using the CH11 anti-CD95 moAb is cases according to their maturational stage did not reveal any shown in Figure 5 . The apoptotic cell fraction (subset 'a') can significant differences in the spontaneous apoptosis rate (data be seen as a subpopulation of cells with lower forward scatter not shown).
and lower DNA content compared with normal cells (subset To test a possible involvement of autocrine CD95-CD95L 'n'). We further separated these subpopulations by flow cytointeractions in the spontaneous apoptosis, several leukemia metry and analyzed their morphological appearance by consamples (12 of T and eight of B lineage ALL) were incubated focal laser microscopy ( Figure 6 ). The microscopic analysis in the presence of the soluble antagonistic anti-CD95 moAb showed characteristic morphological changes of the PI-(clone ZB4) which has been demonstrated to block CD95L-stained nuclei of the cells from the apoptotic but not from the induced apoptosis. 35 No differences were found for cells incuviable cell fraction (subset 'a' vs subset 'n', Figure 6 ). bated with medium alone or with the antagonistic CD95 moAb at concentrations between 0.1 g and 10 g of antibody per 10 6 leukemic cells (data not shown). These data indiExpression of CD95 and bcl-2 and CD95-mediated cate that the spontaneous apoptosis of most ALL cells is not apoptosis in human leukemia T and B cell lines triggered by an autocrine CD95/CD95L interaction.
We additionally investigated expression of bcl-2 and CD95 as well as CD95-mediated apoptosis in several leukemia B and T cell lines. As shown in Table 2 , leukemia cell lines revealed a broader range of CD95 expression as compared with that of leukemic samples of ALL patients (1.9-29 RFI vs 1.07-16 a Cells were incubated with the indicated anti-CD95 moAb for 20 h at 37°C, assessed for apoptosis by flow cytometry and the specific CD95-mediated apoptosis was calculated as described in Materials and methods. Experiments were performed at least twice Figure 4 Distribution of spontaneous apoptosis rates associated with the B and T lineage ALLs. The rate of spontaneous apoptosis was for each leukemia sample. Rates of specific apoptosis were 27 and 37%.
Figure 6
Confocal microscopy of nuclei from non-apoptotic (A) or apoptotic (B) leukemia cells. Apoptotic and non-apoptotic T lineage ALL cells were separated by flow sorting after 20 h of incubation with the anti-CD95 moAb (subsets 'a' and 'n' of Figure 5 ). Fluorescence from PI-stained nuclei was collected as a three-dimensional sequence of fluorescence intensities of volume elements (voxels) with a 0.11 × 0.11 × 0.29 m 3 size and reconstructed as a surface-shaded Figure 5 Spontaneous and CD95-mediated apoptosis of T lineage projection using the ImageSpace software (Molecular Dynamics). ALL (mature T-ALL) cells detected by flow cytometry. The cells were Scale bar = 1 m. cultured in standard medium with the absence or presence of anti-CD95 (clone CH11) moAb for 20 h at 37°C. Subpopulation of apoptotic cells ('a') can be readily distinguished from normal, nonapoptotic cells ('n') in the density plot of linear DNA content vs forward scatter.
Only in 5% of cases did the apoptosis rate exceed the 20%
In the example shown, the spontaneous apoptosis rate was 30% and level of specific apoptosis. Overall, the rate of CD95-induced the detected CD95-specific apoptosis 26%. apoptosis did not correlate with the expression level of CD95. Similarly, the CD95-induced apoptosis rate was not associated with the expression level of the bcl-2 protein, despite its RFI, respectively). By contrast, bcl-2 levels did not vary significantly and, generally, were lower than in ALL samples constitutive expression in leukemic cells. Compared with leukemic cell samples from ALL patients, CD95 expression and (mean RFI = 2.8 vs 5.6, respectively).
sensitivity to CD95 triggering in human leukemia cell lines were found to be extremely variable, with some of them showing high levels of both parameters. However, no clearDiscussion cut correlation between these parameters could be found. In fact, the cell lines with different levels of CD95 expression, In the present study, we investigated the expression and function of the CD95 (Fas/APO-1) antigen on leukemic blasts from eg BV-173 (RFI = 4) and 207 (RFI = 22), exhibited comparable extents of CD95-mediated apotosis. By contrast, two cell lines 95 patients with B or T lineage ALL. All samples studied were found to express surface CD95 with expression levels, howwith similar levels of CD95 expression, MOLT-3 and PF-382, were either resistant (PF-382) or highly sensitive (MOLT-3) to ever, varying considerably between very low (RFI = 1.07) and high (RFI = 16). Despite its constitutive expression, the CD95 CD95-triggering. These data are consistent with recent studies 28,38 which did not reveal a significant association of protein was either unable to initiate apoptosis of leukemic cells upon the oligomerization by anti-CD95 antibodies (75% expression and functionality of CD95 in leukemia cell lines.
A comparison of B and T lineage ALL revealed significant of cases) or induced low rates of apoptosis (20% of cases). Table 2 CD95-sensitivity of T and B leukemia cell lines in relation paring mean values, T lineage ALL were found to express to expression levels of CD95 and bcl-2 more CD95 protein and to be more sensitive to CD95 triggering compared with B lineage ALL. The latter finding indi- acute leukemias, the bcl-2 protein was detected both in AML 50, 51 and B and T lineage ALL. 52-54 Additionally, its a Cells were stained by direct immunofluorescence using either antiexpression level was found to be increased in AML 55 and in inducing cytotoxic drugs, as well as with a low complete remission rate after intensive chemotherapy of AML patients. 24, 50, 57 In contrast, an influence of the bcl-2 differences in the expression levels of CD95 but not of the bcl-2 protein. T lineage ALL cells expressed significantly more expression on the outcome was not yet observed in ALL patients treated with intensive chemotherapy.
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CD95, and most cases sensitive to CD95-mediated apoptosis were observed among T lineage ALL (38 vs 10%). InterestIn accordance with the central role of bcl-2 in the inhibition of apoptosis, its expression has been shown to correlate ingly, the rate of spontaneous apoptosis of the leukemic cells upon culturing in vitro was significantly higher in T than in B reciprocally with the susceptibility of cells to CD95-mediated apoptosis. Thus, resting T lymphocytes express high levels of lineage ALL samples. However, further subclassification of T and B lineage ALL according to their maturational stage did bcl-2 and are highly resistant to CD95 triggering, while activated T cells express low amounts of bcl-2 and are CD95-not reveal significant differences as to the expression of CD95 and bcl-2 or the apoptotic behavior of the cells.
sensitive. 58 A similar relationship was found in B cells, monocytes and neutrophils. 47 Despite this correlation between bclOur findings indicating that all ALL samples studied expressed, at least very weakly, the CD95 antigen are in line 2 expression and CD95-susceptibility, a direct interference of bcl-2 with the apoptotic signalling triggered by the CD95 syswith recent reports on CD95 expression in malignant hematopoietic cells. Thus, CD95 was detected on the majority of tem has not been shown unequivocally. Thus, although a transfection with human bcl-2 gene resulted in an inhibition myeloma cells, 39, 40 in adult T cell leukemias, 41 acute myeloid leukemias 42 and B or T lineage ALL. 28 It should be noted that of anti-Fas-mediated cell death in a murine cell line, this inhibition was only partial. 26 Furthermore, the negative selection the antigen expression in these studies has been assessed by flow cytometry, a method which is more sensitive than a during the thymocyte development was found to use two different pathways, one being Fas-mediated but bcl-2 indesemiquantitative assessment of immunofluorescence using fluorescence microscopy. This fact may explain a significantly pendent and the other Fas-independent and bcl-2-sensitive.
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The resistance or low susceptibility to CD95 in leukemic lower number of CD95 positive cases (10%) in acute leukemia investigated by the latter method in another recent study. 43 cells could be ascribed to the increased bcl-2 presence in leukemic cells if compared with their normal counterparts. 55, 56 Although CD95 is broadly expressed on normal and malignant blood cells, its functional importance for triggering of However, the absence of quantitative correlation between expression of bcl-2 and sensitivity to CD95 triggering in our apoptosis could be observed only in a limited number of cell lineages. Thus, the crosslinking of CD95 by antibody or by study as well as in other reports 28, 39 suggests that the expression and complex interactions of other members of the its natural APO-1/Fas ligand was demonstrated to be highly effective in activated peripheral T and B lymphocytes, [44] [45] [46] bcl-2 family, such as bak, bax, bad, mcl-1, bcl-X L and bcl-X S , being involved in the intracellular apoptotic signalling promature neutrophils 47 and, with regard to malignant cells, in adult T cell leukemia, 41, 48 as well as partially in AML cells. 42 cess, have to be taken into consideration. 49 The expression of these members of the bcl-2 family in ALL is presently under Most malignant cells such as myeloma cells, 39,40 AML 42 and B and T lineage ALL cells 28 failed to undergo CD95-mediated investigation.
Considering the resistance to CD95-mediated apoptosis, apoptosis, and additional treatment of the cells was necessary to overcome their refractoriness to CD95 triggering. 15, 28, 40, 42 defects in the cytoplasmic domain of the CD95 molecule ('death domain'), homologous to that of TNF receptor, cannot Our results obtained by analyzing a large series of ALL samples demonstrate a low susceptibility of ALL cells to CD95 be excluded. Thus, mutations of the 'death domain' were found to prevent cytotoxicity mediated by CD95L or TNF. 60 triggering, thus supporting previous observations that the expression of CD95 on the surface of leukemic cells alone is In addition, the observed resistance to apoptosis may be due to defects on the level of cysteine proteases of ICE family not sufficient for CD95-induced apoptosis. 28 Moreover, there was no quantitative correlation between CD95 expression and involved in execution of apoptosis. 61 However, the CD95 refractory ALL cells were observed to undergo spontaneous sensitivity to CD95 in individual samples, although, by com- 
